Efficacy and Safety of PARPi to Treat Pancreatic Cancer
Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, phase II trial of Olaparib for PDAC patients with
BRCAness. All study subjects will receive Olaparib in a dose of 300 mg p.o twice daily.
Treatment will continue until progression, intolerable toxicity or as per patient preference.
Primary objective:
To determine the efficacy of Olaparib monotherapy in stage IV pancreatic ductal
adenocarcinoma (PDAC)with BRCAness (BRCA-Breast Cancer susceptibility gene).